Muzamil Saleem

Muzamil is a neuroscientist with diverse research experience in the fields of developmental neurobiology, Alzheimer’s disease and the neuroimmunology of chronic pain. He received a Bachelor's degree with honors in Clinical Sciences, and a Master's degree in Neuroscience—both from King’s College London, UK, followed by a Ph.D. in Neuroscience from Duquesne University, Pittsburgh, USA

His research career began at the Centre for Developmental Neurobiology, King’s College London, investigating the effect of retinoic acid concentration gradients and its metabolizing genes in the developing chick embryo, under the supervision of Professor Malcolm Maden. Work at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, contributed to the development of a plasma biomarker panel of proteins to predict preclinical Alzheimer’s disease, in the laboratory of Professor Simon Lovestone. Predoctoral research at the University of Pittsburgh focused on investigating the cellular and molecular mechanisms of neurodegeneration, using genetically modified mouse models. The work sought to explore the role of lipid-associated genes in the pathogenesis of Alzheimer's disease. Muzamil’s doctoral research has demonstrated nanomedicine-driven chronic pain relief in a rat model, whilst revealing aspects of the underlying macrophage and mast cell neurobiology.

He was awarded a predoctoral fellowship in 2011 by the University of Pittsburgh to research the role of lipid associated genes in the pathogenesis of Alzheimer’s disease. In 2015, his doctoral research was awarded the Gerald F Gebhart Distinguished Research Prize by the University of Pittsburgh, USA.